Collagen Crosslinking

Delta Eye has been offering collagen crosslinking, an exciting technology to stop and partially reverse the progression of keratoconus, as part of an ACOS/AVEDRO sponsored FDA clinical trial (ACOS-KXL-001).  We are currently on hold enrolling and treating patients with keratoconus and post surgical ectasia pending probable FDA approval this summer.  The FDA is allowed us to treat patients as young as 12 years of age.  We will update this information as it becomes available.  For any additional information on crosslinking please see the following links: